Global

Oncology Experts

George R. Blumenschein

Professor
Thoracic Head and Neck Medical Oncology
MD Anderson Cancer Center
United States of America

Biography

Dr. George R. Blumenschein, Jr is a Professor of Medicine in Department of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. He received his B.A. from Vanderbilt University and his M.D. degree from University of Texas Medical School in Houston. He completed his residency in internal medicine at The University of Texas Health Science Center in Houston and his fellowship training in medical oncology at The University of Texas MD Anderson Cancer Center. He joined The University of Texas MD Anderson Cancer Center in 2000 as an Instructor of Medicine. He was promoted to Assistant Professor of Medicine in 2001. He is board certified in both internal medicine and medical oncology. Dr. Blumenschein is a member of ASCO, SWOG, RTOG, and AACR. He has authored or co-authored papers and book chapters regarding the management of lung and head and neck cancers. Dr Blumenschein’s area of focus is in new drug development and multimodality therapy for the treatment of lung and head and neck cancers. Specifically, he is interested in the utilization of compounds with novel mechanisms of action in clinical trials for the treatment of these tumors. He serves as the principle investigator on a number of research protocols.

Research Interest

Thoracic Head and Neck Medical Oncology

Publications

  • Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials Oncotarget 5 (19) :8937-8946, 2014.

  • Komaki R, Paulus R, Blumenschein GR, Curran WJ, Robert F, Thariat J, Werner-Wasik M, Choy H, Hirsch FR, Ang KK EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: A secondary analysis of RTOG 0324. Radiother Oncol 112 (1) :30-6, 2014

  • Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers Head Neck 37 (5) :644-649, 2015.

Global Experts from United States of America

Global Experts in Subject

Share This Profile
Recent Expert Updates
  • Matthew L Stone
    Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.   Matthew
    Dr. Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone Matthew
    Dr. L Stone Matthew
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  L Stone
    Dr. L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr. Matthew L Stone
    Dr. Matthew L Stone
    pediatrics
    University of Virginia Health System; Charlottesville, VA
    United States of America
  • Dr.  R Sameh
    Dr. R Sameh
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   R Ismail,
    Dr. R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Sameh R Ismail,
    Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   Sameh R Ismail,
    Dr. Sameh R Ismail,
    pediatrics
    King Abdul Aziz University
    United Arab Emirates
  • Dr.   William
    Dr. William
    pediatrics
    Maimonides Medical Center
    United States of America